REGENERYS.COM

regenerx.com

Utilizing Thymosin Beta 4 (Tβ4) to develop drug candidates in three principal areas: dermal, ophthalmic, and cardiovascular wound healing. - RegeneRx

Pipeline / Clinical Trials. SNNLive interview with J.J. Finkelstein, President and CEO of RegeneRx Biopharmaceuticals, Inc. at the 4th Annual SeeThruEquity MicroCap Investor Conference 2015 in New York City, NY. Watch the video interview. Shareholder letter - Tuesday February 17, 2015. August 12, 2015. New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders. August 6, 2015. RegeneRx Provides Update on Clinical Trials in U.S., Korea and China. July 22, 2015.

regenerx.investorroom.com

RegeneRx Investors - Overview

Pipeline / Clinical Trials. To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. More. View Letter to Shareholders. Aug 12, 2015. New Publication Elaborates on TB4's Effects on Dry Eye Syndrome and Other Potential Ophthalmic Disorders. Aug 6, 2015. RegeneRx Provides Update on Clinical Trials in U.S., Korea and China. Jul 22, 2015. No events to display. July 15, 2014. July 7, 2014. June 23, 2014.

regenerxx.com

Index of /

Apache Server at www.regenerxx.com Port 80.

regenerxxl.com

regenerxxl.com

Inquire about this domain.

regenery.com

NetBeat Webhosting - www.netbeat.de

Wir wuenschen Ihnen viel Spaß mit NetBeat Webhosting.

regenerys.com

Home – Regenerys

Innovative solutions for regenerative medicine. Regenerys is a regenerative medicine company working with adipose tissue for breast reconstruction and plastic surgery, and in skin regeneration technology. We are HTA and MHRA licenced and are built on solid pillars of quality, regulatory compliance and experienced staff. The leadership team is advised by pre-eminent clinicians. Welcome to the new site! June 15, 2015. 2015 Regenerys Ltd. tel: 0114 222 0989 email: info@regenerys.com.

regenes.com

TopDomainer Search Engine

3,50000 €. 7,08000 €. 1,00000 €. 20,000.00 €. 7,00000 €. 30,000.00 €. 5,90000 €. 20,000.00 €. 8,26000 €. 1,00000 €. 20,000.00 €. 30,000.00 €. 4,72000 €. 2,78500 €. 9,74700 €. 3,54000 €. 5,90000 €. 3,54000 €. 3,54000 €. 18,000.00 €. 5,31000 €. 4,13000 €. 4,72000 €. 18,000.00 €. 4,13000 €. 7,08000 €. 7,08000 €. 3,54000 €. 5,29000 €. 5,31000 €. 4,17700 €. 7,08000 €. 4,13000 €. 5,31000 €. 5,31000 €. 14,160.00 €. 5,90000 €. 8,54000 €. 3,54000 €. 5,31000 €. 3,54000 €. 2,95000 €. 5,90000 €. 5,31000 €. 4,13000 &...

regenes.info

トップページ

regenes.is

Regenesis | Regenesis

Regenesis is based around our local university and college chapters. We believe that lasting environmental change starts with young people. Working on campuses and in local communities, in collaboration with others, we design, plan, facilitate and operate initiatives and programs. Grassroots Participation –. Partnerships and Collaboration –. Social Enterprise –. Ensuring the long-term viability of our programs and services is critical. As such, we take an entrepreneurial approach to our activities in...

regenesance-pharma.com

Home

Regenesance, developing novel treatments. For immune mediated and neurodegenerative disorders. First Therapeutic Product Focus. Regenesance is developing a line of products based on proprietary monoclonal antibodies to inhibit formation of the Membrane Attack Complex (MAC) part of the complement pathway. Regenesance is focused on developing treatments for the orphan drug indications. Regenesance presenting on BioCapital Europe. March 26, 2015. EPIC Biotech, October 2015.

regenesance.com

Default PLESK Page

This is the Plesk™ default page. If you see this page it means:. 1) hosting for this domain is not configured. 2) there's no such domain registered in Plesk. For more information please contact .